Hormone Therapy May Change a Tumor's Address

Prostate cancer imaging has spent the past decade learning to look for one especially useful address: PSMA.

That address has changed the field. If a prostate tumor displays enough prostate-specific membrane antigen, a radiotracer can find it on a PET scan. In some patients, a related radioactive drug can then deliver treatment to cells carrying the same marker. The idea is elegant enough that it has become almost a new mental model for cancer medicine: do not just ask where the tumor is; ask what address it is showing.

But a new first-in-human imaging study adds a more unsettling twist. A tumor’s address may not be fixed.

In 23 men with biopsy-confirmed prostate cancer, researchers compared a standard PSMA-targeted PET tracer with an experimental neurotensin receptor 1, or NTSR1, tracer called [18F]-AlF-NOTA-neurotensin before surgery. In untreated patients, PSMA won easily. The PSMA tracer localized 36 of 38 lesion foci, while the NTSR1 tracer identified none at the lesion level.

Then the story flipped.

Among men who had received short-term androgen-deprivation therapy — hormone therapy meant to suppress prostate-cancer signaling — PSMA sensitivity dropped, while NTSR1 sensitivity rose. Tissue staining moved in the same direction: PSMA expression fell and NTSR1 expression increased after treatment.

The golden nugget is not that NTSR1 is suddenly better than PSMA. The study is small, single-center, and early. The more interesting idea is stranger: cancer treatment may change the molecular label a tumor presents to the outside world. A scan that works before therapy may become less informative after therapy, while a different address may become newly visible.

That turns radiopharmaceutical oncology from a static map into something closer to traffic tracking.

The old scan was a snapshot

A PET scan can feel definitive because the image is so concrete. A lesion lights up. A physician sees where disease is hiding. A patient sees dots on a screen.

But the light is not the tumor itself. It is the result of a molecular match: a tracer found enough of the right target, stayed there long enough, and produced a signal strong enough to separate tumor from background noise.

PSMA has become one of prostate cancer’s most important molecular handles. Despite its name, it is not perfectly limited to prostate tissue, and not every prostate cancer displays it the same way. Still, PSMA-targeted imaging has become powerful because many prostate cancers show enough of the marker to make disease visible in places conventional imaging can miss.

The clinical imagination that followed was obvious: if a molecule can find PSMA for imaging, a similar targeting strategy might carry therapeutic radiation. That is the theranostic dream — first use the address to see the disease, then use the address to attack it.

But that dream depends on the address being present when it matters.

Hormone therapy may remodel the sign on the door

Androgen-deprivation therapy, or ADT, is one of the basic tools of prostate cancer treatment. It lowers or blocks androgen signaling, which many prostate cancer cells use as growth fuel. In ordinary language, it tries to starve the tumor of a hormonal accelerator.

The new NTSR1 imaging paper suggests that this pressure may also alter what the tumor displays.

In the untreated group, the PSMA tracer behaved like the dominant tool. The experimental neurotensin-based tracer looked weak by comparison. That matters: it argues against a simplistic reading where NTSR1 is just a universal upgrade. Before ADT, at least in this small study, PSMA was the far better address.

After short-term ADT, however, the pattern changed. The paper reports lower PSMA staining and higher NTSR1 staining in tumor tissue, with imaging performance shifting in the same direction. The provocative implication is that treatment may push some tumors into a different surface identity.

Think of it less like a house moving and more like the sign on the building changing. The structure is still there. The disease is still prostate cancer. But the molecular label that a radiotracer can recognize may be different after therapy.

For radiopharmaceutical medicine, that is a big conceptual shift. It means patient selection may eventually depend not only on cancer type and location, but on treatment timing. The right scan before therapy may not be the right scan after therapy. The right target in a treatment-naive tumor may not be the right target in a hormonally stressed one.

Why NTSR1 is interesting

NTSR1 is a receptor for neurotensin, a peptide involved in nervous-system and gastrointestinal signaling. In cancer research, it has attracted attention because some tumors overexpress it, making it a potential target for imaging or therapy.

That does not make it easy.

A recent review of NTSR1-targeted radiopharmaceuticals notes that both peptide and non-peptide ligands are being studied, including agents that have entered clinical trials. The attraction is familiar: if a tumor displays enough NTSR1, a radioactive ligand might find it. The obstacles are also familiar: tumor-to-background contrast, kidney accumulation, pharmacokinetics, and the still-unfinished task of building reliable diagnostic-and-therapeutic pairs.

In other words, NTSR1 is not yet a clean replacement address. It is a candidate address with a lot to prove.

That is why the prostate cancer study is interesting not as a victory lap, but as a clue. It suggests NTSR1 may be more relevant in a specific biological context: after androgen signaling has been suppressed. If that pattern holds in larger studies, NTSR1 imaging could become less a general prostate-cancer scan and more a way to read how the tumor has changed under treatment pressure.

That would fit a broader movement in oncology. Cancer is not a static object. It adapts, selects, loses markers, gains markers, and changes under the pressure of therapy. Radiopharmaceuticals are often described as precision tools, but precision may require repeated measurement. The address book may need updating.

The commercial and clinical stakes

The business story around radiopharmaceuticals has been intense because the category combines diagnostics, targeted therapy, nuclear-medicine infrastructure, isotope supply chains, and oncology drug development. It is not just a molecule story. It is a system story.

PSMA showed what happens when a target becomes clinically useful enough to reorganize care pathways. Imaging, referral patterns, patient selection, manufacturing, reimbursement, nuclear pharmacy logistics, and therapy development all start orbiting the same molecular address.

If prostate cancer or other tumors can shift addresses after treatment, the next layer of competition may not be one target versus another. It may be sequencing: which tracer should be used at which disease stage, after which therapy, and for which downstream treatment option?

That is where peptide-based and peptide-inspired radioligands become especially important. Small targeting molecules can be redesigned, relabeled, tuned with linkers, modified to change clearance, or paired with different radioactive cargo. The field is not only trying to find better tumor addresses. It is trying to build a flexible delivery language around them.

The strongest version of the NTSR1 story would be a future where a patient whose disease becomes less PSMA-visible after hormonal therapy is not simply harder to image. Instead, the tumor’s new biology reveals another route.

The weaker version is that this small study reflects a narrow context, technical constraints, or a signal that does not translate into better clinical decisions. Both are possible.

The boundary

This is still early evidence.

The study included 23 men at a single center, and the post-ADT subgroup was small. The most striking flip in tracer performance needs replication in larger and more diverse populations, including metastatic disease settings where imaging decisions often carry major treatment consequences.

There is also a difference between seeing an address and using it therapeutically. A tracer that lights up disease does not automatically prove that enough radioactive payload can be delivered safely and effectively to change outcomes. NTSR1-targeted radiopharmaceuticals still face the usual hard questions: background uptake, kidney exposure, tumor retention, isotope choice, dosing, manufacturing, and whether imaging predicts benefit.

The cleanest future test is not simply whether NTSR1 can make pretty scans. It is whether NTSR1 imaging after hormonal therapy identifies patients who would otherwise be missed, changes management, or opens a real treatment route.

That is the unresolved question now. Prostate cancer medicine already learned that tumors can be treated as addresses. The next lesson may be more complicated: under pressure, the address can change.